Endogenous nonapeptide neuropeptide/hormone

Plain-language summaryIntrigue 72 / 100

Oxytocin is the social bonding and childbirth hormone, a 9-amino-acid peptide. Used clinically to induce labor and control postpartum bleeding. Off-label and research interest in social bonding, autism spectrum disorders, and PTSD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Canonical OTR probe with clean obstetric evidence; intranasal CNS research has largely underdelivered

Look, oxytocin is one of those compounds where the story sounds better than the data actually reads. It’s an endogenous nonapeptide, hypothalamic origin, posterior pituitary release. The basic biology has been textbook for decades. The FDA approval for labor induction and postpartum hemorrhage is real and well-earned; that translational arrow is clean and strong. But that’s not why most research groups are pulling it off the shelf today.

The interesting research angle has been intranasal oxytocin for autism spectrum disorder, PTSD, social anxiety, and pair bonding. This has been one of the more disappointing stories in translational neuropharmacology over the last fifteen years. The Simon Baron-Cohen and Ernst Fehr groups generated genuinely exciting early data around 2010-2013 on social cognition and trust behavior. The mechanism story was compelling: OTR activation in the amygdala modulating threat appraisal, OTR in the nucleus accumbens influencing reward-based social behavior. It made sense on paper.

Then replication hit this literature hard. The Bethlehem et al. (2017) Lancet Psychiatry RCT in ASD, multi-site and well-powered, didn’t find meaningful benefit. The Guastella group’s replication work showed high effect-size heterogeneity across studies. The core problem, which still isnt resolved, is whether intranasal oxytocin actually reaches the brain in meaningful concentrations. Some investigators argue it acts peripherally on vagal afferents and OTR in circumventricular organs. Others think direct CNS entry occurs but in a dose and individual-variable manner. That debate is live and unresolved, and it cuts directly at the bench utility of the compound for the programs investigators care about most.

We think the bench value remains real for specific programs. If you’re running a social behavior study in rodents, investigating OTR distribution, or studying parturition physiology, oxytocin is what you need and thats not changing. The pharmacology around OTR subtypes, signal bias, and receptor trafficking is genuinely active and underexplored at the mechanistic level. What we dont like is the enthusiasm that still surrounds the psychiatric indications given how consistently those trials have underperformed.

The mechanism is single-receptor, known for decades, not unusual. Differentiation is structural: it’s the canonical OTR agonist and theres no real alternative probe, but that’s a position of necessity rather than pharmacological innovation. Evidence quality overall sits high because of the approved use and massive literature base, but for the research indications most investigators actually care about, the signal is frankly thin. Oxytocin belongs in your library if you’re doing OTR biology or reproductive physiology; for social cognition and psychiatric programs, honest assessment suggests the field has more questions than answers, and the translational promise hasn’t materialized.

Novelty: 22
Mechanism promise: 30
In-category differentiation: 45
Evidence quality: 60
Translational signal: 35
Research bench value: 55

Rationale Oxytocin is the reference compound for OTR biology with a massive, FDA-backed evidence base in reproductive medicine, but the headline research angle (intranasal delivery for autism, PTSD, social cognition) has produced mixed-to-negative results across multiple large RCTs, and CNS penetration after intranasal administration remains mechanistically contested, deflating novelty, mechanism, and translational scores significantly.

Endogenous nonapeptide neuropeptide/hormone

An endogenous nonapeptide produced in the hypothalamus and released by the posterior pituitary, with maternal, social bonding, and anxiolytic effects.

Abstract

Oxytocin (CAS 50-56-6; molecular formula C43H66N12O12S2; molecular weight 1007.19) is an endogenous nonapeptide hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released systemically by the posterior pituitary. The compound is FDA-approved for labor induction and postpartum hemorrhage (intravenous). Beyond reproductive applications, intranasal oxytocin has been studied extensively for autism spectrum disorder, social anxiety, PTSD, and pair bonding research, with mixed clinical results. Mechanism is oxytocin receptor (OTR) agonism. Pharmacokinetics: plasma half-life ~3 to 6 minutes; central CNS penetration after intranasal administration is debated. Doses for research applications are typically 24 IU intranasally per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-135Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Endogenous nonapeptide neuropeptide/hormone

Oxytocin

Abstract

Read the full monograph